Unigene Laboratories, Inc. (OTC:UGNE) has announced that it has filed a shelf registration statement on Form S-3 with the Securities and Exchange Commission (SEC). The registration statement is declared effective by the SEC, the company will be able to offer and sell one or more public offering up to $30 million of equity or debt securities. No immediate plans have been made as of yet to sell securities.
Penny Stock Professor, a leading financial publication, is pleased to alert investors of stocks on the move. Sign Up for our Free Penny Stock Picks.
A biopharmaceutical company, Unigene is focused on the oral and nasal delivery of large-market peptide drugs. The company is targeting its efforts on the development of calcitonin and PTH based therapies. It’s primary nasal calcitonin product is Fortical® for the treatment of postmenopausal osteoporosis.
Follow us on Twitter: http://www.twitter.com/pennystockspro
Sign up for the free Penny Stock Professor newsletter. To subscribe, enter your e-mail address into the frame at the bottom of this press release or visit our website.
About Us
Penny Stock Professor is a leading stock web site that allows investors and interested parties to research stocks that are on the move. We also track small cap companies that are on the brink of a financial breakout. To feature a company on our web site please contact us at the email listed below.
Please click here to read the full disclaimer.
